FLJ46875: A Potential Drug Target for LOC440918 Family Members

Target Name: FLJ46875

NCBI ID: G440918

FLJ46875

Other Name(s): Uncharacterized LOC440918 | uncharacterized LOC440918

FLJ46875: A Potential Drug Target for LOC440918 Family Members

FLJ46875 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LOC440918 family, which is a group of transmembrane proteins that play a role in various cellular processes.

The LOC440918 family has been identified as a potential drug target due to its involvement in a variety of physiological processes, including cell signaling, migration, and inflammation. The family members are involved in the regulation of actinin, a protein that is involved in cell-cell and cell-extracellular matrix interactions, as well as in the regulation of adherens junction, a protein that is involved in cell-cell adhesion.

FLJ46875 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is highly conserved, with a calculated pI of 4.76 and a predicted localization in the endoplasmic reticulum. FLJ46875 is a monomer and has a molecular weight of 46.87 kDa.

FLJ46875 is involved in a variety of cellular processes, including cell signaling, migration, and inflammation. One of its functions is to regulate the activity of the protein FAK, which is involved in cell adhesion, migration, and invasion. FLJ46875 has been shown to interact with FAK and regulate its activity in various cellular contexts.

FLJ46875 has also been shown to be involved in the regulation of the cytoskeleton. It is a component of the microtubules, which are the protein structures that make up the cytoskeleton and provide structural support for the cell. The cytoskeleton plays a role in cell

Protein Name: Uncharacterized LOC440918

The "FLJ46875 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ46875 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets